Data / Drug companies / Strategic Sourcing Services LLC
Strategic Sourcing Services LLC: 288 products in the FDA NDC directory, labeler code 70677
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Strategic Sourcing Services LLC (labeler code 70677) lists 288 products in the FDA National Drug Code Directory, covering 135 finished drugs by generic name. By type: 288 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on October 20, 2026.
The request: Watch Strategic Sourcing Services LLC (FDA labeler code 70677): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70677
- Products in commercial distribution
- 288
- Packages
- 365
- Finished drugs by generic name
- 135
- Prescription products
- 0
- Over the counter products
- 288
- Flagged as original packager
- 267 of 267 products that carry the flag
- Started marketing in the last 12 months
- 13
- Products with a marketing end date set
- 16
- Earliest marketing start
- June 15, 1992
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 162 | 56.2% |
| Generic drugs (ANDA) | 115 | 39.9% |
| New drug applications (NDA) | 8 | 2.8% |
| Other unapproved drugs | 3 | 1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 288 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 35 | 12.2% |
| Tablet, film coated | 28 | 9.7% |
| Suspension | 22 | 7.6% |
| Liquid | 21 | 7.3% |
| Solution | 21 | 7.3% |
| Cream | 15 | 5.2% |
| Tablet, extended release | 13 | 4.5% |
| Tablet, chewable | 13 | 4.5% |
| Lozenge | 11 | 3.8% |
| Capsule, liquid filled | 10 | 3.5% |
| Solution/ drops | 10 | 3.5% |
| Tablet, delayed release | 9 | 3.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Foster and Thrive Regular Strength Pain Relief Acetaminophen 325mg | 70677-1302 | Tablet | Over the counter monograph drugs | October 20, 2026 |
| Maximum Strength Mucus Relief | 70677-1320 | Tablet, extended release | Generic drugs (ANDA) | September 9, 2026 |
| Foster and Thrive Senna-S Sennosides and Docusate Sodium Laxative and Stool Softener | 70677-1309 | Tablet | Over the counter monograph drugs | September 1, 2026 |
| Stool Softener | 70677-1318 | Tablet | Over the counter monograph drugs | June 1, 2026 |
| Castor Oil | 70677-1317 | Liquid | Over the counter monograph drugs | May 1, 2026 |
| Foster and thrive aspirin | 70677-1310 | Tablet, delayed release | Over the counter monograph drugs | April 1, 2026 |
| Foster and thrive allergy and congestion d | 70677-1315 | Tablet, film coated, extended release | Generic drugs (ANDA) | February 11, 2026 |
| Foster and Thrive Cherry Cough Drops | 70677-1298 | Lozenge | Over the counter monograph drugs | February 1, 2026 |
| Foster and Thrive Honey Lemon Cough Drops | 70677-1297 | Lozenge | Over the counter monograph drugs | February 1, 2026 |
| Foster and Thrive SF Honey Lemon Cough Drops | 70677-1296 | Lozenge | Over the counter monograph drugs | February 1, 2026 |
| Foster and Thrive Daytime Cold and Flu Relief | 70677-1313 | Tablet, film coated | Over the counter monograph drugs | January 18, 2026 |
| Foster and thrive all day allergy d | 70677-1311 | Tablet, film coated, extended release | Generic drugs (ANDA) | December 10, 2025 |
| Pinworm treatment | 70677-1312 | Suspension | Over the counter monograph drugs | December 5, 2025 |
| Foster and thrive miconazole 1 | 70677-1294 | Kit | Generic drugs (ANDA) | October 1, 2025 |
| Foster and thrive arthritis pain | 70677-1293 | Gel | Generic drugs (ANDA) | September 27, 2025 |
| Foster and Thrive Ibuprofen | 70677-1282 | Capsule, liquid filled | Generic drugs (ANDA) | July 8, 2025 |
| Foster and thrive hemorrhoidal | 70677-1292 | Suppository | Over the counter monograph drugs | June 11, 2025 |
| Motion Sickness | 70677-1290 | Tablet, chewable | Over the counter monograph drugs | May 30, 2025 |
| Childrens Pain and Fever | 70677-1286 | Suspension | Over the counter monograph drugs | May 27, 2025 |
| Foster and thrive mucus relief | 70677-1291 | Tablet, multilayer, extended release | Generic drugs (ANDA) | May 21, 2025 |
| Fexofenadine HCL | 70677-1256 | Tablet | Generic drugs (ANDA) | May 1, 2025 |
| Foster and thrive anti itch cream | 70677-1289 | Cream | Over the counter monograph drugs | April 30, 2025 |
| Foster and thrive pain reliever | 70677-1271 | Suppository | Generic drugs (ANDA) | April 15, 2025 |
| Foster and Thrive Pain Reliever | 70677-1270 | Suppository | Generic drugs (ANDA) | April 7, 2025 |
| Calamine | 70677-1316 | Lotion | Over the counter monograph drugs | April 1, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.